A clinical need exists for a sensitive and specific assay for the quantitation of the bone isoform of alkaline phosphatase in serum. The majority of methods do not meet this requirement; however, the recent development of immunoassays for this isoform may provide a solution. In a detailed evaluation of two immunoassays, we found a degree of imprecision that enables the discrimination of changes within the reference range. The cross-reactivity of the liver isoform was found to be between 7.1% and 12.7% when two different methods of assessment were used. The comparison of results with an electrophoretic procedure showed that the immunocapture method recovered less of the bone isoform in samples from children than in samples from patients with Paget disease; no such difference was found with the immunometric method. This suggests that the immunocapture antibody may discriminate between different bone isoforms in children whereas the immunometric assay does not.
The bone isoform of alkaline phosphatase (ALP) is a member of the so-called tissue-nonspecific isoenzyme family, which also comprises the liver and kidney isoforms. These three main isoforms are thought to differ primarily in the degree of posttranslational glycosylation [1, 2] . Additional isoforms demonstrated in vesicular structures are thought to be a consequence of shedding of the enzyme attached to its membrane anchor region [3] .
Many things may cause increases of ALP activity in serum, the most common being obstructive liver disease and metabolic bone disease. An increase of the liver or particularly the bone isoform in serum can provide valuable diagnostic information. It is rare that the kidneyderived isoform appears in the circulation, and whereas an increase of the intestinal, placental, or germ cell isoenzymes is more common, this is of limited diagnostic value except in some patients with malignant disease.
The analytical challenge therefore is to achieve specific quantitation of the liver and bone isoforms. This has been attempted with several techniques, including heat inactivation [4] , wheat germ lectin precipitation [5] , electrophoresis [6] , isoelectric focusing [7] , HPLC [8, 9] , and immunoassay [10, 11] . The nonimmunological techniques have in some instances failed to provide the required sensitivity or specificity, whereas some of the separation techniques have identified multiple fractions (bands) that have confused interpretation. In this respect, the primary clinical application is quantitation of the bone isoform, and although several immunoassays for this isoform have been described, only two have been validated in any detail [11] [12] [13] [14] [15] [16] [17] [18] [19] .
The two immunoassays that have received the most attention are based on immunometric [12] and immunocapture [11] principles. The former detects bound isoform with a labeled second monoclonal antibody, whereas the latter measures the activity captured, in both cases, to a solid-phase-bound monoclonal antibody. Enzyme derived from a human osteosarcoma cell line is needed as a calibrator in both methods. However, the published validations of these methods have resulted from a range of comparison methods to assess accuracy and, in particular, the cross-reactivity with the liver isoform. The results reported have thus been very variable. In an earlier study [19] , we found a significant difference in the correlation of results by the immunocapture method and by an electrophoretic technique, when studying samples from children and from patients with Paget disease. We did not observe such a difference in patient groups when assessing the immunometric assay [14] . We have therefore set out to validate both immunoassay methods with the use of the same samples and identical comparison procedures. Particular attention was paid to comparison with a nonimmunological method that achieved complete discrimina-tion between liver and bone isoforms, and to assessment of apparent cross-reactivity of the liver isoform.
Materials and Methods measurement of total alp activity
The total ALP activity was measured with the use of a centrifugal analyzer (Monarch ® , Instrumentation Laboratory). Briefly, 3 L of serum was mixed with 160 L of p-nitrophenyl phosphate in a 2-amino-2-methyl-1-propane buffer at pH 10.5. The reaction was monitored at 405 nm for a total of 3 min after an incubation temperature of 37°C was reached, and the activity was calculated with reference to the absorptivity of the product.
electrophoresis with neuraminidase pretreatment An aliquot of sample (50 L) was incubated with 10 L of neuraminidase (2000 U/L) at 20°C for 10 min, and 5 L of the mixture was applied to a preprepared gel (Isopal Plus, Beckman Instruments); an aliquot of untreated sample was also analyzed. Current was applied at a constant 150 V for 25 min. The gel was then incubated with freshly prepared substrate for 15 min at 37°C. The gel was then rinsed in water and acetic acid and dried. Quantitation of the isoforms was performed by densitometry (Model GS-60 Imaging Densitometer, Bio-Rad Labs.); the socalled high-M r liver isoform was quantitated from densitometry of the untreated sample separation.
immunometric assay Serum or calibrator (100 L), together with 100 L of 125 I-labeled anti-bone ALP (mouse) monoclonal antibody was added to a tube containing a bead coated with a second anti-bone ALP (mouse) monoclonal antibody. All tubes were incubated for 19 Ϯ 2 h at 4°C with the tubes partially immersed in a tray of water. The beads were then rinsed three times with a detergent solution, and the total and bound radioactivity was counted in an NE 1600 counter (Nuclear Enterprises). All calibrator and sample measurements were performed in duplicate, and results were expressed in g/L. The calibrator was prepared from the SAOS-2 human osteosarcoma cell line and supplied in a liquid form. The reagents were supplied by Hybritech.
immunocapture assay An aliquot (125 L) of reaction buffer followed by 20 L of sample or calibrator was added to wells of a microtiter plate coated with an anti-bone ALP (mouse) monoclonal antibody. The microtiter plate was covered and incubated at room temperature for 3 h, followed by removal of the contents and washing of the wells with a buffered detergent solution. To each well was then added 150 L of buffered p-nitrophenyl phosphate, pH 10.4, and the contents were incubated at room temperature for 30 min. The reaction was stopped by the addition of 100 L of 1 mol/L sodium hydroxide, and the absorbance was read at 405 nm with an automated microtiter plate reader (Molecular Devices). The assay was calibrated with the use of bone ALP obtained from the SAOS-2 human osteosarcoma cell line, and the results were reported as U/L at 37°C (conversion from results at 25°C was established in a separate experiment [19] ). The reagents were supplied by Metra Biosystems.
samples Serum samples were collected from children with no evidence of bone disease and admitted to the hospital for another reason, patients with Paget disease, and patients with obstructive liver disease. All samples were stored at Ϫ20°C until analysis, and all analyses on a sample were performed within 7 h of its thawing.
Results imprecision
Two serum pools were prepared containing different concentrations of bone ALP, and the pools were aliquotted and stored at Ϫ20°C. One aliquot of each pool was thawed and analyzed in duplicate on each day when another experiment was performed. The between-batch imprecision for the two immunoassay methods is shown in Table 1 .
comparison of results
The bone ALP isoform concentration was determined by the two immunoassay methods and the electrophoretic method for samples from children and from patients with Paget disease. The data are shown in Figs. 1-3 .
cross-reactivity of liver isoform
The assessment of cross-reactivity of the liver isoform was undertaken by two approaches: heat inactivation, and addition of liver ALP.
Heat inactivation. A total of 27 serum samples known to contain various proportions of the bone and liver isoforms (from electrophoretic evaluation) were used. For each sample, a 400-L aliquot of sample was placed in each of 6 thin-walled glass tubes. The tubes were placed in a water bath at 56°C and removed after 7.5, 15, 20, 25, or 30 min; each tube was then placed in a tray of crushed ice. The total ALP and the bone ALP isoform was quantitated in the latter by all three methods described. The ratio of apparent bone ALP to total ALP was calculated at each of the incubation points, and the data for the two immuno- assays are shown in Table 2 . The electrophoretic method confirmed that no bone ALP activity remained after heating of the sample for 25 min at 56°C. The cross-reactivity of the liver isoform in the immunometric assay was calculated from the ratio of apparent bone ALP to total ALP for the liver isoform remaining after heating at 56°C for 25 min divided by the same ratio for the bone isoform in serum from patients with Paget disease (i.e., the slope of the regression line in Figs. 1 and  2 ). This gave a figure for cross-reactivity (mean Ϯ SD) of 7.1% Ϯ 2.32% (i.e., 2.88 Ϭ 0.407 ϫ 100 ϭ 7.1%) for the immunometric assay. The comparable calculation for the immunocapture assay gave a figure of cross-reactivity of 7.9% Ϯ 1.41% (i.e., 7.17 Ϭ 0.906 ϫ 100 ϭ 7.91%).
Addition of liver ALP.
A series of samples containing either predominantly liver or bone ALP were obtained. A sample containing predominantly liver isoform was added (to 10%, 20%, 30%, 40%, and 50% of the final volume) to a constant amount of serum from a patient with Paget disease (50% of the final volume) with the difference made up with human serum albumin (40 g/L in 0.9 g/L NaCl). All mixtures were assayed by both immunoassays, whereas the original materials were also assayed by the electrophoretic method to confirm the predominance (Ͼ95%) of one of the isoforms. The total ALP of the samples containing the liver isoform was also determined. The apparent bone ALP increase resulting from added liver ALP was then plotted against the ALP activity and added, and the data are shown in Figs. 4 and 5. The figure for cross-reactivity is obtained from the ratio of apparent bone ALP to total ALP for the sera from patients with Paget disease (i.e., the slopes in Figs. 1 and 2 ). The 
Discussion
This study produced results for imprecision comparable with those reported in earlier evaluations [11] [12] [13] [14] [15] [16] [17] [18] [19] . Most importantly, it confirmed some of the results obtained in previous method comparisons, but not others [14, 16, 19] ; thus whereas the immunometric assay showed concordance in the relation between mass and activity in samples from children and patients with Paget disease, the same was not true in the case of the immunocapture assay. The cross-reactivity of the liver isoform is very similar for both immunoassay methods and uses two different experimental approaches. There is no ideal approach to the assessment of cross-reactivity, especially when it has been shown that analysis of a purified fraction of the liver isoform gave 100% cross-reactivity [14] . The use of heat-inactivation studies assumes that all specimens have an identical inactivation profile, which is known not to be the case [4] ; furthermore, the technique assumes that catalytic activity and immunoactivity are equally sensitive to elevated temperatures. By use of this approach with the immunocapture assay, Gomez et al.
[11] studied five samples from patients with liver disease and found the cross-reactivity to be within the range of 3% to 8%; our data showed a mean of 7.9% with a range of 5.8% to 10.0% when we studied 27 samples. A similar experiment in which the immunometric assay was used with the same samples and the apparent bone ALP:total ALP ratio of the heat-inactivated sample was compared with the ratio in sera from patients with Paget disease indicated a mean cross-reactivity of 7.0% with a range of 3.2% to 10.6%. This is the first instance where this approach has been used with the immunometric method. Hata et al. [15] used the heat-inactivation approach with the immunocapture assay and found a cross-reactivity of 8.7% with the liver isoform. The addition of liver isoform in serum from patients with obstructive liver disease to a serum containing bone isoform and measurement of the apparent increase in bone ALP indicated a cross-reactivity of 8.6% in the immunocapture assay and 12.7% in the immunometric assay. This result is based on the correlation data shown in Table 2 . These data compare with similar figures in previous evaluations [14, 19] .
Withold et al. [16] and Garnero and Delmas [13] studied the cross-reactivity of the immunocapture and immunometric assays, respectively, by comparing the ratio of apparent bone ALP to total ALP in sera from patients with liver disease and found mean cross-reactivities of 20% and 16%, respectively. This approach assumes that no bone isoform is present in the sera of patients with liver disease, which is unlikely to be the case, especially in chronic liver disease. Consequently, these figures are probably an overestimate of cross-reactivity. Panigrahi et al. [12] studied the cross-reactivity of the liver isoform in the immunometric assay by enriching heat-inactivated serum with a series of dilutions of sera from patients with predominantly bone or liver ALP present. The ratio of apparent bone ALP mass to total ALP activity was calculated for the bone and liver dilutions; the ratio of the liver dilutions was 14.7% of the bone dilutions, indicating the amount of cross-reactivity. Again, on the basis that the ratio of mass to activity did not change in the majority of samples, the authors concluded that each sample contained only one isoform; this figure may therefore reflect an overestimate of the cross-reactivity. The immunometric assay showed a relation similar to that found with a catalytic method as that found by Garnero and Delmas [13] and Panigrahi et al. [12] . All of these studies used serum samples from patients with a range of metabolic bone disorders.
None of the previous studies has independently assessed the comparison of results by different methods with samples from children and from patients with Paget disease; our studies have shown a difference in the relation between activity captured by the monoclonal antibody and that found by the electrophoretic method. No difference was found with the immunometric assay in this or in a previous study [14] . The observations made with the immunocapture assay may be due to (a) a different specific activity of the bone isoform present in children compared with patients with Paget disease; (b) differences in the posttranslational modification, which alters the epitope that is recognized in the immunocapture assay; or (c) the presence of different isoforms of bone origin, the proportions of which differ in the subject groups studied. It is unlikely that a difference in specific activity accounts for the observation; otherwise, differences would have been noted in the immunometric assay. The possibility of variations in posttranslational modification influencing either the conformation of the epitope or the production of a subfamily of isoforms is possible. The broad distribution of the bone isoform after electrophoresis points to a heterogeneity of sialylation-treatment with neuraminidase producing a more discrete band. Furthermore, both isoelectric focusing and HPLC separations have identified more than one bone isoform, although the predominance of individual fractions in particular diseases has not been reported [7, 9, 21] . Miura et al. [22] studied the sugar moieties with the use of two neuraminidases and O-glycanase and concluded that the structural epitope differences between liver and bone ALP may depend on the nearby O-linked sugar moieties as well as sialic acid residues. The authors did not, however, link the variations to any particular type of bone disease. Schoneau et al. [23] , using anion-exchange chromatography, found two bone isoforms in sera of children, and Parviainen et al. [9] found that one isoform predominated in sera from patients with osteoporosis, osteomalacia, bone metastases, and Paget disease. Onica et al. [24] found two bone fractions on electrophoresis, and Anderson et al. [25] also found evidence of change in the glycosylation of bone ALP in patients with bone disease. Langlois et al. [26] compared the immunometric assay with the electrophoretic technique used in this study and found that the ratio of activity to mass was substantially lower in patients with hyperthyroidism than in controls and patients with osteoporosis; this was considered to reflect a difference in posttranslational modification in different pathological conditions.
The literature shows that different isoforms of bone ALP exist; the immunocapture method appears to recognize an isoform that is different from that recognized by the immunometric assay. At this stage, the clinical significance of this observation is not clear, albeit there is an apparent reduction in the detection limit compared with the electrophoretic method. The application of a sensitive assay for bone ALP in children in clinical practice is not apparent to date, in part because of the large biological variation in this analyte in children; however, it might be important in children with metabolic bone disease in that the relative increase will be diminished.
